1. Home
  2. ACAD vs NAMS Comparison

ACAD vs NAMS Comparison

Compare ACAD & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACAD
  • NAMS
  • Stock Information
  • Founded
  • ACAD 1993
  • NAMS 2019
  • Country
  • ACAD United States
  • NAMS Netherlands
  • Employees
  • ACAD N/A
  • NAMS N/A
  • Industry
  • ACAD Biotechnology: Pharmaceutical Preparations
  • NAMS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACAD Health Care
  • NAMS Health Care
  • Exchange
  • ACAD Nasdaq
  • NAMS Nasdaq
  • Market Cap
  • ACAD 3.4B
  • NAMS 2.7B
  • IPO Year
  • ACAD 2004
  • NAMS N/A
  • Fundamental
  • Price
  • ACAD $19.95
  • NAMS $18.57
  • Analyst Decision
  • ACAD Buy
  • NAMS Strong Buy
  • Analyst Count
  • ACAD 19
  • NAMS 7
  • Target Price
  • ACAD $25.33
  • NAMS $41.33
  • AVG Volume (30 Days)
  • ACAD 1.6M
  • NAMS 618.3K
  • Earning Date
  • ACAD 02-26-2025
  • NAMS 03-04-2025
  • Dividend Yield
  • ACAD N/A
  • NAMS N/A
  • EPS Growth
  • ACAD N/A
  • NAMS N/A
  • EPS
  • ACAD 0.78
  • NAMS N/A
  • Revenue
  • ACAD $929,236,000.00
  • NAMS $33,594,000.00
  • Revenue This Year
  • ACAD $36.88
  • NAMS $131.53
  • Revenue Next Year
  • ACAD $8.01
  • NAMS N/A
  • P/E Ratio
  • ACAD $25.70
  • NAMS N/A
  • Revenue Growth
  • ACAD 47.06
  • NAMS 78.77
  • 52 Week Low
  • ACAD $14.15
  • NAMS $15.19
  • 52 Week High
  • ACAD $26.56
  • NAMS $27.29
  • Technical
  • Relative Strength Index (RSI)
  • ACAD 60.25
  • NAMS 29.65
  • Support Level
  • ACAD $19.52
  • NAMS $18.88
  • Resistance Level
  • ACAD $20.29
  • NAMS $20.46
  • Average True Range (ATR)
  • ACAD 0.68
  • NAMS 1.11
  • MACD
  • ACAD 0.08
  • NAMS -0.09
  • Stochastic Oscillator
  • ACAD 72.62
  • NAMS 5.84

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Share on Social Networks: